ANTI-CD22 IMMUNOTOXIN/ANTIBODY-DRUG CONJUGATE
Lumoxiti is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults with relapsed or refractory hairy cell leukemia. Lumoxiti is indicated in cases where two prior therapies, including a purine nucleoside analog, have failed. Lumoxiti may also be referred to by its drug name, moxetumomab pasudotox-tdfk.
Lumoxiti is an antibody-drug conjugate consisting of two parts. Moxetumomab is a biologic drug — a genetically engineered protein, or antibody — that targets the CD22 protein on B cells. Pasudotox is the first drug in a class called anti-CD22 immunotoxins. Lumoxiti is believed to work by delivering the powerful toxin directly to leukemia cells, inhibiting protein synthesis and resulting in cell death.
How do I take it?
Lumoxiti is administered as an intravenous infusion on days 1, 3, and 5 in a 28-day cycle.
Lumoxiti comes in the form of a single-dose vial.
The FDA-approved label for Lumoxiti lists common side effects including headache, fever, fatigue, nausea, diarrhea, constipation, anemia, and edema (swelling).
Rare but serious side effects listed for Lumoxiti include kidney damage, infusion reactions, and fetal harm in pregnant women. Lumoxiti can also cause capillary leak syndrome and hemolytic uremic syndrome, both life-threatening conditions involving the blood vessels.
For more details about this treatment, visit:
Lumoxiti — Innate Pharma
HCL: Relapsed and Refractory — Leukemia and Lymphoma Society